CDK9 and cancer: Although recently clinically evaluated targets, such as BRD4, the Mediator complex, and the CDK7-TFIIH and CDK9-pTEFb complexes, are common binding proteins on transcriptional regulatory elements, they are highly enriched in oncogenic SEs; therefore, their inhibition preferentially impacts genes with oncogenic SEs and shows relative selectivity to cancer cells.